Analysis of pretransplant risk factors for the development of TA-TMA
| Variables . | TA-TMA incidence, % . | Univariate . | Multivariate . | ||
|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | ||
| Age, y | |||||
| <50 | 4.1 | Reference | Reference | ||
| ≥50 | 5.8 | 1.46 (1.02-2.10) | .04* | 1.35 (0.92-1.99) | .12 |
| Sex | |||||
| Female | 4.5 | Reference | |||
| Male | 5.3 | 1.14 (0.79-1.64) | .49 | ||
| PS | |||||
| 0-1 | 4.3 | Reference | Reference | ||
| 2-4 | 8.1 | 1.94 (1.27-2.96) | <.01* | 1.69 (1.09-2.61) | .01* |
| HCT-CI | |||||
| 0-2 | 5.0 | Reference | Reference | ||
| 3- | 9.0 | 1.81 (1.09-2.99) | .02* | 1.65 (0.91-2.59) | .10 |
| Disease | |||||
| ALL | 5.3 | Reference | |||
| AML MDS | 4.0 | 0.75 (0.45-1.26) | .28 | ||
| NHL | 6.3 | 1.27 (0.70-2.32) | .44 | ||
| ATL | 6.2 | 1.20 (0.53-2.72) | .67 | ||
| CML | 4.9 | 0.93 (0.32-2.67) | .89 | ||
| MM | 8.3 | 1.61 (0.60-4.28) | .34 | ||
| AA | 1.7 | 0.31 (0.04-2.30) | .25 | ||
| Disease risk | |||||
| Standard | 4.1 | Reference | |||
| High | 5.9 | 1.43 (0.99-2.05) | .05 | ||
| Prior allo-HSCT | |||||
| N | 4.6 | Reference | |||
| Y | 6.9 | 1.52 (0.99-2.31) | .05 | ||
| Conditioning | |||||
| MAC | 5.3 | Reference | |||
| RIC | 5.1 | 0.97 (0.68-1.39) | .88 | ||
| Donor source | |||||
| Rel-BM | 2.6 | Reference | Reference | ||
| Rel-PB | 5.0 | 2.00 (0.98-4.06) | .06 | 1.55 (0.77-3.12) | .21 |
| UR-BM | 4.6 | 1.87 (0.99-3.56) | .06 | 1.17 (0.61-2.22) | .63 |
| CB | 7.1 | 2.89 (1.53-5.43) | <.01* | 1.18 (0.60-2.30) | .61 |
| HLA mismatch | |||||
| Matched | 2.8 | Reference | Reference | ||
| Mismatched | 6.4 | 2.25 (1.48-3.43) | <.01* | 2.17 (1.34-3.52) | <.01* |
| Sex mismatch | |||||
| Matched | 4.4 | Reference | |||
| F to M | 5.9 | 1.34 (0.86-2.07) | .20 | ||
| M to F | 5.0 | 1.19 (0.75-1.89) | .46 | ||
| ABO mismatch | |||||
| Matched | 5.4 | Reference | |||
| Major | 5.3 | 0.96 (0.59-1.57) | .87 | ||
| Minor | 6.6 | 1.21 (0.79-1.85) | .38 | ||
| Major-Minor | 3.1 | 0.55 (0.25-1.21) | .14 | ||
| GVHD prophylaxis | |||||
| CyA-based | 4.5 | Reference | |||
| FK506-based | 5.2 | 1.17 (0.79-1.74) | .43 | ||
| Year of HSCT | |||||
| 2000-2009 | 4.4 | Reference | |||
| 2010-2016 | 5.5 | 1.29 (0.90-1.85) | .17 | ||
| Variables . | TA-TMA incidence, % . | Univariate . | Multivariate . | ||
|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | ||
| Age, y | |||||
| <50 | 4.1 | Reference | Reference | ||
| ≥50 | 5.8 | 1.46 (1.02-2.10) | .04* | 1.35 (0.92-1.99) | .12 |
| Sex | |||||
| Female | 4.5 | Reference | |||
| Male | 5.3 | 1.14 (0.79-1.64) | .49 | ||
| PS | |||||
| 0-1 | 4.3 | Reference | Reference | ||
| 2-4 | 8.1 | 1.94 (1.27-2.96) | <.01* | 1.69 (1.09-2.61) | .01* |
| HCT-CI | |||||
| 0-2 | 5.0 | Reference | Reference | ||
| 3- | 9.0 | 1.81 (1.09-2.99) | .02* | 1.65 (0.91-2.59) | .10 |
| Disease | |||||
| ALL | 5.3 | Reference | |||
| AML MDS | 4.0 | 0.75 (0.45-1.26) | .28 | ||
| NHL | 6.3 | 1.27 (0.70-2.32) | .44 | ||
| ATL | 6.2 | 1.20 (0.53-2.72) | .67 | ||
| CML | 4.9 | 0.93 (0.32-2.67) | .89 | ||
| MM | 8.3 | 1.61 (0.60-4.28) | .34 | ||
| AA | 1.7 | 0.31 (0.04-2.30) | .25 | ||
| Disease risk | |||||
| Standard | 4.1 | Reference | |||
| High | 5.9 | 1.43 (0.99-2.05) | .05 | ||
| Prior allo-HSCT | |||||
| N | 4.6 | Reference | |||
| Y | 6.9 | 1.52 (0.99-2.31) | .05 | ||
| Conditioning | |||||
| MAC | 5.3 | Reference | |||
| RIC | 5.1 | 0.97 (0.68-1.39) | .88 | ||
| Donor source | |||||
| Rel-BM | 2.6 | Reference | Reference | ||
| Rel-PB | 5.0 | 2.00 (0.98-4.06) | .06 | 1.55 (0.77-3.12) | .21 |
| UR-BM | 4.6 | 1.87 (0.99-3.56) | .06 | 1.17 (0.61-2.22) | .63 |
| CB | 7.1 | 2.89 (1.53-5.43) | <.01* | 1.18 (0.60-2.30) | .61 |
| HLA mismatch | |||||
| Matched | 2.8 | Reference | Reference | ||
| Mismatched | 6.4 | 2.25 (1.48-3.43) | <.01* | 2.17 (1.34-3.52) | <.01* |
| Sex mismatch | |||||
| Matched | 4.4 | Reference | |||
| F to M | 5.9 | 1.34 (0.86-2.07) | .20 | ||
| M to F | 5.0 | 1.19 (0.75-1.89) | .46 | ||
| ABO mismatch | |||||
| Matched | 5.4 | Reference | |||
| Major | 5.3 | 0.96 (0.59-1.57) | .87 | ||
| Minor | 6.6 | 1.21 (0.79-1.85) | .38 | ||
| Major-Minor | 3.1 | 0.55 (0.25-1.21) | .14 | ||
| GVHD prophylaxis | |||||
| CyA-based | 4.5 | Reference | |||
| FK506-based | 5.2 | 1.17 (0.79-1.74) | .43 | ||
| Year of HSCT | |||||
| 2000-2009 | 4.4 | Reference | |||
| 2010-2016 | 5.5 | 1.29 (0.90-1.85) | .17 | ||
Statistically significant.